Expression of Lysophosphatidic Acid Receptor 1 and Relation with Cell Proliferation, Apoptosis, and Angiogenesis on Preneoplastic Changes Induced by Cadmium Chloride in the Rat Ventral Prostate

PLoS ONE

Volumn 8, Issue 2, 2013, Pages

  Arriazu, Riánsares ^a   Durán, Esther ^a   Pozuelo, José M ^a   Santamaria, Luis ^b  

^a UNIVERSIDAD SAN PABLO CEU   (Spain)

^b AUTONOMOUS UNIVERSITY OF MADRID   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CADMIUM CHLORIDE; LYSOPHOSPHATIDIC ACID RECEPTOR; LYSOPHOSPHATIDIC ACID RECEPTOR 1; PROTEIN BCL 2; PROTEIN P53; UBIQUITIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DYSPLASIA; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE VENTRAL LOBE; PROTEIN EXPRESSION; QUALITATIVE ANALYSIS; QUANTITATIVE ANALYSIS; RAT; TUMOR VASCULARIZATION;

ANIMALS; APOPTOSIS; CADMIUM CHLORIDE; CELL GROWTH PROCESSES; MALE; MICROVESSELS; MINICHROMOSOME MAINTENANCE COMPLEX COMPONENT 7; NEOVASCULARIZATION, PATHOLOGIC; PRECANCEROUS CONDITIONS; PROLIFERATING CELL NUCLEAR ANTIGEN; PROSTATE; PROSTATIC NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, LYSOPHOSPHATIDIC ACID; TUMOR SUPPRESSOR PROTEIN P53; UBIQUITIN;

EID: 84874326591     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0057742     Document Type: Article

References (49)

1. Lin CE, Chen SU, Lin CC, Chang CH, Lin YC, et al. (2012) Lysophosphatidic acid enhances vascular endothelial growth factor-C expression in human prostate cancer PC-3 cells. PLoS One 7: e41096.
2. Aimola P, Carmignani M, Volpe AR, Di Benedetto A, Claudio L, et al. (2012) Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. PLoS One 7: e33647.
3. Bonkhoff H, Remberger K, (1998) Diagnostic criteria and differential diagnosis of prostatic intraepithelial neoplasia. Pathologe 19: 33-41.
4. Marshall JR, (2001) High-grade prostatic intraepithelial neoplasia as an exposure biomarker for prostate cancer chemoprevention research. IARC Sci Publ 154: 191-198.
5. Nicholson B, Theodorescu D, (2003) Molecular therapeutics in prostate cancer. Histol Histopathol 18: 275-298.
6. Arriazu R, Pozuelo JM, Martin R, Rodriguez R, Santamaria L, (2005) Quantitative and Immunohistochemical Evaluation of PCNA, Androgen Receptor, Apoptosis and Glutathione-S-Transferase P1 on Preneoplastic Changes Induced by Cadmium and Zinc Chloride in the Rat Ventral Prostate. Prostate 63: 347-357.
7. Arriazu R, Pozuelo JM, Rodriguez R, Henriques-Gil N, Perucho T, et al. (2005) Cadmium and zinc chloride-induced preneoplastic changes in the rat ventral prostate: An immunohistochemical and molecular study. In: Jonathan J Li, Sara A LI, Antonio LLombart-Bosch, editors. Hormonal Carcinogenesis IV. Springer. pp. 522-528.
8. Arriazu R, Pozuelo JM, Henriques-Gil N, Perucho T, Martín R, et al. (2006) Immunohistochemical Study of Cell Proliferation, Bcl-2, p53 and Caspase-3 Expression on Preneoplastic Changes Induced by Cadmium and Zinc Chloride in the Ventral Rat Prostate. J Histochem Cytochem 54: 981-90.
9. Yamashita H, Tripathi M, Jourquin J, Kam Y, Liu S, et al. (2010) Lysophosphatidic Acid Upregulates Laminin-332 Expression during A431 Cell Colony Dispersal. J Oncol 2010. pii: 107075. Epub; 2010 Aug 25: 107075.
10. Chen SU, Lee H, Chang DY, Chou CH, Chang CY, et al. (2008) Lysophosphatidic acid mediates interleukin-8 expression in human endometrial stromal cells through its receptor and nuclear factor-kappaB-dependent pathway: a possible role in angiogenesis of endometrium and placenta. Endocrinology 149: 5888-5896.
11. Guo R, Kasbohm EA, Arora P, Sample CJ, Baban B, et al. (2006) Expression and function of lysophosphatidic acid LPA1 receptor in prostate cancer cells. Endocrinology 147: 4883-4892.
12. Murph MM, Nguyen GH, Radhakrishna H, Mills GB, (2008) Sharpening the edges of understanding the structure/function of the LPA1 receptor: expression in cancer and mechanisms of regulation. Biochim Biophys Acta 1781: 547-557.
13. Yanagida K, Ishii S, (2011) Non-Edg family LPA receptors: the cutting edge of LPA research. J Biochem 150: 223-232.
14. Yanagida K, Masago K, Nakanishi H, Kihara Y, Hamano F, et al. (2009) Identification and characterization of a novel lysophosphatidic acid receptor, p2y5/LPA6. J Biol Chem 284: 17731-17741.
15. Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, et al. (2010) LPA receptors: subtypes and biological actions. Annu Rev Pharmacol Toxicol 50: 157-86 doi:10.1146/annurev.pharmtox.010909.105753.: 157-186.
16. Chen M, Towers LN, O'Connor KL, (2007) LPA2 (EDG4) mediates Rho-dependent chemotaxis with lower efficacy than LPA1 (EDG2) in breast carcinoma cells. Am J Physiol Cell Physiol 292: C1927-C1933.
17. Sumida H, Noguchi K, Kihara Y, Abe M, Yanagida K, et al. (2010) LPA4 regulates blood and lymphatic vessel formation during mouse embryogenesis. Blood 116: 5060-5070.
18. Lundequist A, Boyce JA, (2011) LPA5 is abundantly expressed by human mast cells and important for lysophosphatidic acid induced MIP-1beta release. PLoS One 6: e18192.
19. Martens-Uzunova ES, Jalava SE, Dits NF, van Leenders GJ, Moller S, et al. (2012) Diagnostic and prognostic signatures from the small non-coding RNA transcriptome in prostate cancer. Oncogene 31: 978-991.
20. Zhu G, Wang X, Yang Z, Cao H, Meng Z, et al. (2011) Effects of TRPM8 on the proliferation and angiogenesis of prostate cancer PC-3 cells in vivo. Oncol Lett 2: 1213-1217.
21. Arakawa A, Soh S, Chakraborty S, Scardino PT, Wheeler TM, (1997) Prognostic significance of angiogenesis in clinically localized prostate cancer (staining for Factor VIII-related antigen and CD34 Antigen. Prostate Cancer Prostatic Dis 1: 32-38.
22. O'Brien TS, Harris AL, (1995) Angiogenesis in urological malignancy. Br J Urol 76: 675-682.
23. Pollard M, Wolter W, Sun L, (2001) Diet and the duration of testosterone-dependent prostate cancer in Lobund-Wistar rats. Cancer Lett 173: 127-131.
24. Morrissey C, Buser A, Scolaro J, O'Sullivan J, Moquin A, et al. (2002) Changes in hormone sensitivity in the ventral prostate of aging Sprague-Dawley rats. J Androl 23: 341-351.
25. Arunkumar A, Vijayababu MR, Venkataraman P, Senthilkumar K, Arunakaran J, (2006) Chemoprevention of rat prostate carcinogenesis by diallyl disulfide, an organosulfur compound of garlic. Biol Pharm Bull 29: 375-379.
26. Bosland MC, (1999) Use of animal models in defining efficacy of chemoprevention agents against prostate cancer. Eur Urol 35: 459-463.
27. Martin JJ, Martin R, Codesal J, Fraile B, Paniagua R, et al. (2001) Cadmium chloride-induced dysplastic changes in the ventral rat prostate: an immunohistochemical and quantitative study. Prostate 46: 11-20.
28. Gavrieli Y, Sherman Y, Ben Sasson SA, (1992) Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol 119: 493-501.
29. Rittmaster RS, Manning AP, Wright AS, Thomas LN, Whitefield S, et al. (1995) Evidence for atrophy and apoptosis in the ventral prostate of rats given the 5 alpha-reductase inhibitor finasteride. Endocrinology 136: 741-748.
30. Sterio DC, (1984) The unbiased estimation of number and sizes of arbitrary particles using the disector. J Microsc 134: 127-136.
31. Santamaria L, Ingelmo I, Ruiz J, Teba F, Herranz LM, et al. (2008) Stereological estimate of microvessels and the number and proliferation of epithelial and endothelial cells in human normal and pathologic prostate. The Open Prostate Cancer Journal 2: 46-53.
32. Kolonel L, Winkelstein W Jr, (1977) Cadmium and prostatic carcinoma. Lancet 2: 566-567.
33. Aronson KJ, Siemiatycki J, Dewar R, Gerin M, (1996) Occupational risk factors for prostate cancer: results from a case-control study in Montreal, Quebec, Canada. Am J Epidemiol 143: 363-373.
34. Lauwerys RR, Bernard AM, Roels HA, Buchet JP, (1994) Cadmium: exposure markers as predictors of nephrotoxic effects. Clin Chem 40: 1391-1394.
35. Waalkes MP, Rehm S, Riggs LW, Bare RM, Devor DE, et al. (1989) Cadmium carcinogenesis in the male Wistar (Crl(WI)BR) rats: Dose-response analysis of effects of zinc on tumor induction in the prostate and in the testes and at the injection site. Cancer Res 49: 4282-4288.
36. Waalkes MP, (2000) Cadmium carcinogenesis in review. J Inorg Biochem 79: 241-244.
37. Waalkes MP, (2003) Cadmium carcinogenesis. Mutat Res 533: 107-120.
38. Tang DG, Li L, Chopra DP, Porter AT, (1998) Extended survivability of prostate cancer cells in the absence of trophic factors: increased proliferation, evasion of apoptosis, and the role of apoptosis proteins. Cancer Res 58: 3466-3479.
39. Luo JH, (2011) Oncogenic activity of MCM7 transforming cluster. World J Clin Oncol 2: 120-124.
40. Ota T, Clayton AC, Minot DM, Shridhar V, Hartmann LC, et al. (2011) Minichromosome maintenance protein 7 as a potential prognostic factor for progression-free survival in high-grade serous carcinomas of the ovary. Mod Pathol 24: 277-287.
41. Ishino H, Hara Y, Takekoshi S, Teshima T, Teramoto A, et al. (2011) Ki-67 and minichromosome maintenance-7 (MCM7) expression in canine pituitary corticotroph adenomas. Domest Anim Endocrinol 41: 207-213.
42. Knillova J, Kolar Z, (2003) The significance of key regulators of apoptosis in the development and prognosis of prostate carcinoma. I. Proteins of the Bcl-2 family and protein p53. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 147: 3-10.
43. Reisman D, Takahashi P, Polson A, Boggs K, (2012) Transcriptional Regulation of the p53 Tumor Suppressor Gene in S-Phase of the Cell-Cycle and the Cellular Response to DNA Damage. Biochem Res Int 2012:808934. Epub; 2012 Jul 11: 808934.
44. Silvestrini R, Benini E, Daidone MG, Veneroni S, Boracchi P, et al. (1993) p53 as an independent prognostic marker in lymph node-negative breast cancer patients. J Natl Cancer Inst 85: 965-970.
45. Bosari S, Lee AK, Viale G, Heatley GJ, Coggi G, (1992) Abnormal p53 immunoreactivity and prognosis in node-negative breast carcinomas with long-term follow-up. Virchows Arch A Pathol Anat Histopathol 421: 291-295.
46. Kwon J, Wang YL, Setsuie R, Sekiguchi S, Sato Y, et al. (2004) Two closely related ubiquitin C-terminal hydrolase isozymes function as reciprocal modulators of germ cell apoptosis in cryptorchid testis. Am J Pathol 165: 1367-1374.
47. Delves GH, Stewart AB, Cooper AJ, Lwaleed BA, (2007) Prostasomes, angiogenesis, and tissue factor. Semin Thromb Hemost 33: 75-79.
48. Kong D, Li Y, Wang Z, Banerjee S, Sarkar FH, (2007) Inhibition of angiogenesis and invasion by 3,3'-diindolylmethane is mediated by the nuclear factor-kappaB downstream target genes MMP-9 and uPA that regulated bioavailability of vascular endothelial growth factor in prostate cancer. Cancer Res 67: 3310-3319.
49. Zeng Y, Kakehi Y, Nouh MA, Tsunemori H, Sugimoto M, et al. (2009) Gene expression profiles of lysophosphatidic acid-related molecules in the prostate: relevance to prostate cancer and benign hyperplasia. Prostate 69: 283-292.